Insider Selling: Mesa Laboratories (NASDAQ:MLAB) Director Sells $800,090.40 in Stock

Key Points

• Insider sale: Director John James Sullivan sold 7,093 Mesa Laboratories shares for approximately $800,090, reducing his position by 28.46% to 17,834 shares.
• Stock and financial performance: MLAB rose 2.0% to $108.19 and reported quarterly revenue of $60.14 million with earnings of $2.68 per share. The stock trades near its 52-week high and carries a high price-to-earnings ratio of 128.81.
• Dividend and analyst view: Mesa declared a quarterly dividend of $0.16, representing a 0.6% yield, while analysts maintain a consensus “Hold” rating with a $110 price target.

Mesa Laboratories, Inc. (NASDAQ:MLAB - Get Free Report) Director John James Sullivan sold 7,093 shares of Mesa Laboratories stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $112.80, for a total value of $800,090.40. Following the completion of the transaction, the director owned 17,834 shares in the company, valued at $2,011,675.20. The trade was a 28.46% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Mesa Laboratories Trading Up 2.0%

NASDAQ:MLAB traded up $2.15 on Monday, hitting $108.19. 77,359 shares of the stock were exchanged, compared to its average volume of 147,914. The stock has a fifty day moving average of $100.64 and a 200-day moving average of $96.07. The stock has a market cap of $605.40 million, a PE ratio of 128.81 and a beta of 0.92. The company has a current ratio of 1.79, a quick ratio of 1.32 and a debt-to-equity ratio of 0.73. Mesa Laboratories, Inc. has a fifty-two week low of $58.83 and a fifty-two week high of $115.52.

Mesa Laboratories (NASDAQ:MLAB - Get Free Report) last released its quarterly earnings data on Monday, August 10th. The medical instruments supplier reported $2.68 earnings per share for the quarter. Mesa Laboratories had a return on equity of 22.72% and a net margin of 1.92%.The business had revenue of $60.14 million for the quarter.

Mesa Laboratories Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 15th. Stockholders of record on Monday, August 31st will be given a $0.16 dividend. The ex-dividend date of this dividend is Monday, August 31st. This represents a $0.64 annualized dividend and a dividend yield of 0.6%. Mesa Laboratories's dividend payout ratio is presently 76.19%.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Wells Fargo & Company upped their price target on shares of Mesa Laboratories from $94.00 to $110.00 and gave the stock an "equal weight" rating in a research report on Friday. Weiss Ratings raised Mesa Laboratories from a "sell (d)" rating to a "hold (c-)" rating in a research report on Tuesday, August 11th. Finally, Wall Street Zen downgraded Mesa Laboratories from a "strong-buy" rating to a "buy" rating in a report on Saturday. Three analysts have rated the stock with a Hold rating, According to data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $110.00.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of MLAB. Northwestern Mutual Wealth Management Co. boosted its holdings in Mesa Laboratories by 5,366.7% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 328 shares of the medical instruments supplier's stock valued at $26,000 after purchasing an additional 322 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in shares of Mesa Laboratories in the 4th quarter valued at approximately $27,000. Kestra Advisory Services LLC acquired a new position in shares of Mesa Laboratories in the 4th quarter valued at approximately $55,000. BNP Paribas Financial Markets boosted its stake in shares of Mesa Laboratories by 115.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 786 shares of the medical instruments supplier's stock valued at $74,000 after buying an additional 421 shares during the last quarter. Finally, Tower Research Capital LLC TRC lifted its holdings in Mesa Laboratories by 432.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 842 shares of the medical instruments supplier's stock worth $79,000 after buying an additional 684 shares during the last quarter. Institutional investors and hedge funds own 90.60% of the company's stock.

About Mesa Laboratories

Mesa Laboratories, Inc NASDAQ: MLAB is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company's product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source